Sign in / Join Now
ETFs & Funds
Ruthanne Williams Roussel
nice that Motley Fool has called attn to
screen, but "revenue growth over past 3 years" is silly metric for a development co
Add a reply...
Latest StockTalks »
people get VVUS breaking news and analysis by email alert.
Get email alerts on VVUS »
Get latest price
From other sites
Earnings Estimates Moving Higher for VIVUS (VVUS): Time to Buy?
at Zacks.com (Oct 6, 2016)
The Zacks Analyst Blog Highlights: VIVUS, Geron, Achillion Pharmaceuticals, Anika Therapeutics and ANI Pharmaceuticals
at Zacks.com (Oct 5, 2016)
VIVUS Licenses Stendra Rights to Metuchen Pharmaceuticals
at Zacks.com (Oct 4, 2016)
VIVUS (VVUS) Q1 Loss Narrower but Qsymia Sales Decline
at Zacks.com (May 4, 2016)
VIVUS (VVUS) Upgraded to Hold on Strong Fundamentals
at Zacks.com (Apr 11, 2016)